2019-nCoV Vaccine mRNA-1273: all 42 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingNCT07863635Phase 4
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingNCT06585241Phase 4
• Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.RecruitingNCT06441955Phase 4
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldCompletedNCT05375838Phase 1/2Results posted
• COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedNCT05289037Phase 2Results posted
• High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant RecipientsTerminatedNCT05280158Phase 1/2Results posted
• Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).TerminatedNCT05228730Phase 3Results posted
• Assessing Immune Response of Different COVID-19 Vaccines in Older AdultsCompletedNCT05160766Phase 2Results posted
• Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedNCT05119855Phase 3Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• COVID-19 Protection After Transplant Pilot StudyCompletedNCT04969263Phase 2Results posted
• A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedNCT04927065Phase 2/3Results posted
• Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedNCT04889209Phase 1/2Results posted
• A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult ParticipantsCompletedNCT04860297Phase 3Results posted
• A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyCompletedNCT04847050Phase 2Results posted
• A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 VaccineCompletedNCT04811664Phase 3Results posted
• A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCompletedNCT04796896Phase 2/3Results posted
• Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated AdultsCompletedNCT04785144Phase 1Results posted
• COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
• A Study of TAK-919 in Healthy Japanese Adults (COVID-19)CompletedNCT04677660Phase 1/2Results posted
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedNCT04649151Phase 2/3Results posted
• A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19CompletedNCT04470427Phase 3Results posted
• Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and OlderCompletedNCT04405076Phase 2Results posted
• Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)CompletedNCT04283461Phase 1Results posted
• Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19CompletedNCT07279766Phase 4
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingNCT07266558Phase 4
• Immunogenicity After COVID-19 Vaccines in Adapted SchedulesCompletedNCT06189040Phase 4
• COVID-19 Fourth Dose Study in AustraliaWithdrawnNCT05543356Phase 3
• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
• Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)WithdrawnNCT05387317Phase 3
• PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALSStatus unknownNCT05279365Phase 2/3
• Fourth COVID-19 Vaccine Dose- mRNA1273Active, not recruitingNCT05230953Phase 3
• The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 VaccineStatus unknownNCT05132855Phase 1/2
• RECOVAC Repeated Vaccination StudyCompletedNCT05030974Phase 4
• Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to VaccinationWithdrawnNCT04930770Phase 2
• Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA VaccineStatus unknownNCT04900467Not applicable
• Third Dose of Moderna COVID-19 Vaccine in Transplant RecipientsCompletedNCT04885907Phase 4
• A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19CompletedNCT04813796Phase 1
• COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune DiseasesCompletedNCT04806113Phase 3
• Immunocompromised Swiss Cohorts Based Trial PlatformCompletedNCT04805125Phase 3
• Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)Status unknownNCT04748471Phase 2
• Vaccination Against COVID-19 in CancerActive, not recruitingNCT04715438Not applicable

← 2019-nCoV Vaccine mRNA-1273 overview